AUPN366795A0 - Formulation for preventing reproductive function - Google Patents
Formulation for preventing reproductive functionInfo
- Publication number
- AUPN366795A0 AUPN366795A0 AUPN3667A AUPN366795A AUPN366795A0 AU PN366795 A0 AUPN366795 A0 AU PN366795A0 AU PN3667 A AUPN3667 A AU PN3667A AU PN366795 A AUPN366795 A AU PN366795A AU PN366795 A0 AUPN366795 A0 AU PN366795A0
- Authority
- AU
- Australia
- Prior art keywords
- formulation
- reproductive function
- deslorelin
- preventing reproductive
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000001850 reproductive effect Effects 0.000 title abstract 2
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 abstract 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
- 229960005408 deslorelin Drugs 0.000 abstract 2
- 108700025485 deslorelin Proteins 0.000 abstract 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 241000282472 Canis lupus familiaris Species 0.000 abstract 1
- 241000282326 Felis catus Species 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960005309 estradiol Drugs 0.000 abstract 1
- 229930182833 estradiol Natural products 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000002953 phosphate buffered saline Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 229960003604 testosterone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Priority Applications (20)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPN3667A AUPN366795A0 (en) | 1995-06-20 | 1995-06-20 | Formulation for preventing reproductive function |
| AU59927/96A AU701837B2 (en) | 1995-06-20 | 1996-06-20 | Novel formulation for peptide release |
| ES96917292T ES2182983T3 (es) | 1995-06-20 | 1996-06-20 | Formulaciones para la liberacion de peptidos. |
| PCT/AU1996/000370 WO1997000693A1 (en) | 1995-06-20 | 1996-06-20 | Novel formulation for peptide release |
| CA2225796A CA2225796C (en) | 1995-06-20 | 1996-06-20 | Novel formulation for peptide release |
| PT96917292T PT871467E (pt) | 1995-06-20 | 1996-06-20 | Formulacao para a libertacao de peptido |
| NZ309697A NZ309697A (en) | 1995-06-20 | 1996-06-20 | Novel formulation for peptide release |
| SI9630524T SI0871467T1 (en) | 1995-06-20 | 1996-06-20 | Formulation for peptide release |
| AT96917292T ATE223726T1 (de) | 1995-06-20 | 1996-06-20 | Formulierung zur peptidfreisetzung |
| HK99100086.7A HK1014874B (en) | 1995-06-20 | 1996-06-20 | Novel formulation for peptide release |
| DK96917292T DK0871467T3 (da) | 1995-06-20 | 1996-06-20 | Ny formulering til afgivelse af peptid |
| JP50345797A JP4016133B2 (ja) | 1995-06-20 | 1996-06-20 | ペプチド放出のための新規な製剤 |
| CNB961948647A CN1145496C (zh) | 1995-06-20 | 1996-06-20 | 用于肽释放的新型组合物 |
| DE122008000004C DE122008000004I2 (de) | 1995-06-20 | 1996-06-20 | Formulierung zur peptidfreisetzung |
| DE69623652T DE69623652T2 (de) | 1995-06-20 | 1996-06-20 | Formulierung zur peptidfreisetzung |
| EP96917292A EP0871467B1 (en) | 1995-06-20 | 1996-06-20 | Formulation for peptide release |
| US08/981,285 US5925619A (en) | 1995-06-20 | 1996-06-20 | Formulation for peptide release |
| US09/251,411 US6211152B1 (en) | 1995-06-20 | 1999-02-17 | Formulations for peptide release |
| NL300330C NL300330I2 (nl) | 1995-06-20 | 2008-01-08 | Preparaat voor het afgeven van peptiden |
| FR08C0001C FR08C0001I2 (enExample) | 1995-06-20 | 2008-01-10 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPN3667A AUPN366795A0 (en) | 1995-06-20 | 1995-06-20 | Formulation for preventing reproductive function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AUPN366795A0 true AUPN366795A0 (en) | 1995-07-13 |
Family
ID=3788008
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AUPN3667A Abandoned AUPN366795A0 (en) | 1995-06-20 | 1995-06-20 | Formulation for preventing reproductive function |
| AU59927/96A Expired AU701837B2 (en) | 1995-06-20 | 1996-06-20 | Novel formulation for peptide release |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU59927/96A Expired AU701837B2 (en) | 1995-06-20 | 1996-06-20 | Novel formulation for peptide release |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US5925619A (enExample) |
| EP (1) | EP0871467B1 (enExample) |
| JP (1) | JP4016133B2 (enExample) |
| CN (1) | CN1145496C (enExample) |
| AT (1) | ATE223726T1 (enExample) |
| AU (2) | AUPN366795A0 (enExample) |
| CA (1) | CA2225796C (enExample) |
| DE (2) | DE69623652T2 (enExample) |
| DK (1) | DK0871467T3 (enExample) |
| ES (1) | ES2182983T3 (enExample) |
| FR (1) | FR08C0001I2 (enExample) |
| NL (1) | NL300330I2 (enExample) |
| NZ (1) | NZ309697A (enExample) |
| PT (1) | PT871467E (enExample) |
| SI (1) | SI0871467T1 (enExample) |
| WO (1) | WO1997000693A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN366795A0 (en) * | 1995-06-20 | 1995-07-13 | Peptide Technology Limited | Formulation for preventing reproductive function |
| CA2264562C (en) | 1996-08-30 | 2012-01-03 | Peptech Limited | Sustained peptide-release formulation |
| WO2000004897A1 (en) * | 1998-07-20 | 2000-02-03 | Peptech Limited | Bioimplant formulation |
| US8052982B2 (en) * | 1998-07-20 | 2011-11-08 | Peptech Animal Health Pty Limited | Bioimplant formulation comprising lecithin and stearin |
| US6211221B1 (en) * | 1999-04-05 | 2001-04-03 | Johnny W. Peterson | Dietary supplement containing histidine for alleviating dysmenorrhea, endometriosis, and pre-term labor |
| AU2001295359A1 (en) * | 2000-10-30 | 2002-05-15 | University Of Zurich | GnRH analogues for treatment of urinary incontinence |
| GB0221539D0 (en) * | 2002-09-17 | 2002-10-23 | Medical Res Council | Methods of treatment |
| CA2552241C (en) * | 2003-12-30 | 2013-10-01 | Durect Corporation | Co-polymeric devices for controlled release of active agents |
| US20080254086A1 (en) * | 2004-12-23 | 2008-10-16 | Brown James E | Controlled Release Compositions |
| KR20100059863A (ko) * | 2007-09-11 | 2010-06-04 | 몬도바이오테크 래보래토리즈 아게 | 치료제로서의 펩티드 티모신 베타 ４ 단독 또는 세크로핀 ａ와의 배합물의 용도 |
| DE102008015104A1 (de) | 2008-03-19 | 2009-09-24 | Basf Coatings Ag | Beschichtungszusammensetzung, Verfahren zu ihrer Herstellung, ihre Verwendung und mit ihr beschichtete Substrate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS563846B2 (enExample) * | 1972-10-12 | 1981-01-27 | ||
| US4218439A (en) * | 1977-07-14 | 1980-08-19 | The Salk Institute For Biological Studies | Peptide which inhibits gonadal function |
| US4256737A (en) * | 1979-06-11 | 1981-03-17 | Syntex (U.S.A.) Inc. | Long acting depot injectable formulations for LH-RH analogues |
| CA1257199A (en) * | 1986-05-20 | 1989-07-11 | Paul Y. Wang | Preparation containing bioactive macromolecular substance for multi-months release in vivo |
| ATE74009T1 (de) * | 1986-08-11 | 1992-04-15 | American Cyanamid Co | Zusammensetzungen zur parenteralen verabreichung und deren verwendung. |
| US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| US5538739A (en) * | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| US5211952A (en) * | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
| US5470582A (en) * | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| AUPN366795A0 (en) * | 1995-06-20 | 1995-07-13 | Peptide Technology Limited | Formulation for preventing reproductive function |
-
1995
- 1995-06-20 AU AUPN3667A patent/AUPN366795A0/en not_active Abandoned
-
1996
- 1996-06-20 NZ NZ309697A patent/NZ309697A/xx not_active IP Right Cessation
- 1996-06-20 JP JP50345797A patent/JP4016133B2/ja not_active Expired - Lifetime
- 1996-06-20 DE DE69623652T patent/DE69623652T2/de not_active Expired - Lifetime
- 1996-06-20 DE DE122008000004C patent/DE122008000004I2/de active Active
- 1996-06-20 US US08/981,285 patent/US5925619A/en not_active Expired - Lifetime
- 1996-06-20 DK DK96917292T patent/DK0871467T3/da active
- 1996-06-20 SI SI9630524T patent/SI0871467T1/xx unknown
- 1996-06-20 PT PT96917292T patent/PT871467E/pt unknown
- 1996-06-20 EP EP96917292A patent/EP0871467B1/en not_active Expired - Lifetime
- 1996-06-20 CA CA2225796A patent/CA2225796C/en not_active Expired - Lifetime
- 1996-06-20 WO PCT/AU1996/000370 patent/WO1997000693A1/en not_active Ceased
- 1996-06-20 ES ES96917292T patent/ES2182983T3/es not_active Expired - Lifetime
- 1996-06-20 AT AT96917292T patent/ATE223726T1/de active
- 1996-06-20 AU AU59927/96A patent/AU701837B2/en not_active Expired
- 1996-06-20 CN CNB961948647A patent/CN1145496C/zh not_active Expired - Lifetime
-
1999
- 1999-02-17 US US09/251,411 patent/US6211152B1/en not_active Expired - Lifetime
-
2008
- 2008-01-08 NL NL300330C patent/NL300330I2/nl unknown
- 2008-01-10 FR FR08C0001C patent/FR08C0001I2/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU701837B2 (en) | 1999-02-04 |
| EP0871467A4 (en) | 2000-07-05 |
| NL300330I1 (nl) | 2008-03-03 |
| CN1188414A (zh) | 1998-07-22 |
| DE122008000004I1 (de) | 2008-04-17 |
| NZ309697A (en) | 1999-11-29 |
| DK0871467T3 (da) | 2002-12-23 |
| JP4016133B2 (ja) | 2007-12-05 |
| CN1145496C (zh) | 2004-04-14 |
| CA2225796A1 (en) | 1997-01-09 |
| CA2225796C (en) | 2011-09-20 |
| HK1014874A1 (en) | 1999-10-08 |
| DE122008000004I2 (de) | 2009-08-06 |
| EP0871467A1 (en) | 1998-10-21 |
| FR08C0001I1 (enExample) | 2008-03-21 |
| PT871467E (pt) | 2002-12-31 |
| JP2001521482A (ja) | 2001-11-06 |
| US5925619A (en) | 1999-07-20 |
| DE69623652T2 (de) | 2003-05-28 |
| NL300330I2 (nl) | 2008-04-01 |
| DE69623652D1 (de) | 2002-10-17 |
| FR08C0001I2 (enExample) | 2009-11-20 |
| EP0871467B1 (en) | 2002-09-11 |
| ES2182983T3 (es) | 2003-03-16 |
| WO1997000693A1 (en) | 1997-01-09 |
| US6211152B1 (en) | 2001-04-03 |
| ATE223726T1 (de) | 2002-09-15 |
| AU5992796A (en) | 1997-01-22 |
| SI0871467T1 (en) | 2003-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR08C0001I2 (enExample) | ||
| AU582920B2 (en) | Continuous release pharmaceutical compositions | |
| AU4718496A (en) | Use of aerogels in agriculture | |
| CA2223817A1 (en) | Compositions for the treatment of rheumatoid-based arthritic diseases | |
| AU7888398A (en) | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations | |
| NZ283135A (en) | Gel formulation for treatment of skin diseases and disinfection/disinfestation of the skin | |
| AU2002236765A1 (en) | Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent | |
| CA2183549A1 (en) | Acidified nitrite as an antimicrobial agent | |
| MY138883A (en) | Use of asiatic acid for treatment of cencer | |
| PL313223A1 (en) | Nigella sativa as a therapeutic agent | |
| WO2001030802A3 (en) | Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies | |
| WO1997004788A3 (en) | Use of calendula glycosides for the treatment of psoriasis | |
| AU4245289A (en) | Psyllium-containing products | |
| AU5673399A (en) | Compositions and methods for treating intracellular infections | |
| EP0663835A1 (en) | USE OF PARATHORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES FOR THE TREATMENT OF PREGNANCY PROBLEMS. | |
| IL107153A (en) | Pharmaceutical compositions for preventing insulin-dependent diabetes mellitus comprising IL10 and method for their manufacture | |
| WO1994020115A3 (en) | Hyaluronic acid used as a cancer treatment | |
| HUP9802536A3 (en) | Pharmaceutical compositions containing 1,2,4-benzotriazine 1,4-dioxide and use thereof for the preparation of pharmaceutical compositions treating cancer | |
| OA09771A (en) | Asphodelus composition for increasing white blood cell count. | |
| MX9603535A (es) | Nitrito acido como un agente antimicrobiano. | |
| UA30723A (uk) | Спосіб лікування аутоімунних захворювань | |
| BG51699A1 (en) | Stimulating fertility agent |